國家衛生研究院 |
2008-12 |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu, C;Kuo, SH;Hu, FC;Cheng, AL;Shih, JY;Yu, CJ;Lin, CC;Huang, TC;Yang, PC;Yang, CH |
臺大學術典藏 |
2022-08-19T00:21:07Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
CHIUN HSU; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
臺大學術典藏 |
2020-04-10T12:51:22Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Huang T.-C.; Yang P.-C.; Yang C.-H.; Lin C.-C.; Chiun Hsu; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J. |
臺大學術典藏 |
2020-05-26T09:27:21Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Lin C.-C; Huang T.-C; Yang P.-C; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Cheng A.-L; Hu F.-C; Kuo S.-H; Hsu C; Chih-Hsin Yang;Yang P.-C;Huang T.-C;Lin C.-C;Yu C.-J;Shih J.-Y;Cheng A.-L;Hu F.-C;Kuo S.-H;Hsu C |
臺大學術典藏 |
2020-08-13T06:33:59Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Yang C.-H.; Yang P.-C.; Huang T.-C.; Lin C.-C.; Yu C.-J.; Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; JIN-YUAN SHIH |
臺大學術典藏 |
2020-12-02T02:34:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; PAN-CHYR YANG; Yang C.-H. |
臺大學術典藏 |
2021-09-01T01:54:26Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
臺大學術典藏 |
2022-06-27T07:07:53Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; CHONG-JEN YU; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
臺大學術典藏 |
2018-09-10T06:52:59Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial
|
Chiun Hsu and Sung-Hsin Kuo and Fu-Chang Hu and Ann-Lii Cheng and Jin-Yuan Shih and Chong-Jen Yu and Chia-Chi Lin and Tsu-Chen Huang and Pan-Chyr Yang and Chih-Hsin Yang; Chong-Jen Yu; Sung-Hsin Kuo; JIN-YUAN SHIH; ANN-LII CHENG |
國家衛生研究院 |
2015-11 |
Gemcitabine synergistically enhances anti-tumor effects of recombinant immunogen-based cancer immunotherapy
|
Liu, SJ;Chang, LS;Yan, WL;Yeh, YC;Leng, CH |
國家衛生研究院 |
1997-05 |
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
|
Perng, RP; Chen, YM; MingLiu, J; Tsai, CM; Lin, WC; Yang, KY; WhangPeng, J |
臺大學術典藏 |
2021-02-23T08:26:35Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; Lin Z.-Z.; SUNG-HSIN KUO; Cheng A.-L. |
臺大學術典藏 |
2021-08-10T03:53:07Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
SHIH-HUNG YANG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
臺大學術典藏 |
2021-08-11T03:46:51Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; ZHONG-ZHE LIN; Kuo S.-H.; Cheng A.-L. |
臺大學術典藏 |
2021-09-01T01:54:20Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; Lin Z.-Z.; Kuo S.-H.; ANN-LII CHENG |
臺大學術典藏 |
2021-08-12T04:01:31Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
YANG SHIH-HUNG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
臺大學術典藏 |
2022-03-08T03:44:08Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
SHIH-HUNG YANG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
臺大學術典藏 |
2022-06-10T06:11:13Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; ZHONG-ZHE LIN; Kuo S.-H.; Cheng A.-L. |
臺大學術典藏 |
2018-09-10T03:52:56Z |
Gemcitabine-induced acute lipodermatosclerosis-like reaction
|
Chu, C.-Y. and Yang, C.-H. and Chiu, H.-C.; HSIEN-CHING CHIU; CHIA-YU CHU |
國立臺灣大學 |
2001 |
Gemcitabine-Induced Acute Lipodermatosclerosis-Like Reaction
|
朱家瑜; 楊志新; 邱顯清; CHU, CHIA-YU; YANG, CHIH-HSIN; CHIU, HSIEN-CHING |
臺大學術典藏 |
2019-12-04T08:44:23Z |
Gemcitabine-induced acute lipodermatosclerosis-like reaction
|
Chia-Yu Chu;Yang C.-H.;Chiu H.-C.; CHIA-YU CHU; Yang C.-H.; Chiu H.-C. |
臺大學術典藏 |
2019-12-05T06:27:02Z |
Gemcitabine-induced acute lipodermatosclerosis-like reaction
|
Chu C.-Y.;Yang C.-H.;Hsien-Ching Chiu; Chu C.-Y.; Yang C.-H.; HSIEN-CHING CHIU |
臺大學術典藏 |
2020-05-26T09:27:32Z |
Gemcitabine-induced acute lipodermatosclerosis-like reaction
|
Chu C.-Y;Chih-Hsin Yang;Chiu H.-C.; Chu C.-Y; CHIH-HSIN YANG; Chiu H.-C. |
國立成功大學 |
2021-07-8 |
Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells
|
Chang;Yu-Hao;Tam;Hoi-Lam;Lu;Meng-Chien;Huang;Huei-Sheng |
臺北醫學大學 |
2005 |
Gemcitabine/Carboplatin Chemotherapy for pure small cell carcinoma of the prostate: A case report.
|
朱娟秀; Chen KC; Chiu AW; Chiang HS; Chu JS; Cheng CJ; |